CareLit · DOI-Nachweis · Aktuelle Neurologie
Temozolomide plus pegylated liposomal doxorubicine is equal to temozolomide in the first-line treatment of patients with glioblastoma – Phase I/II-study
DOI 10.1055/s-0028-1086672
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Hau, C Schmid, B Hirschmann, C Kleinletzenberger, M Proescholdt, G Stockhammer, A Brawanski, M Hegi, U Bogdahn
ZeitschriftAktuelle Neurologie
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Temozolomide (Temodar® TMZ) recently showed promising efficacy in an EORTC trial on first-line therapy of glioblastoma (GBM). Pegylated liposomal doxorubicin (Caelyx® PEG-Dox) was evaluated in patients with recurrent glioblastoma (GBM) with an overall response rate of 40%. Therefore, a combination regimen seems promising. Methods: TMZ was given orally in a dose of 75mg/m2 daily during involved field radi…
Zitieren
Zitierempfehlung
P Hau, C Schmid, B Hirschmann, C Kleinletzenberger, M Proescholdt, G Stockhammer, A Brawanski, M Hegi, U Bogdahn (2008) Temozolomide plus pegylated liposomal doxorubicine is equal to temozolomide in the first-line treatment of patients with glioblastoma – Phase I/II-study. Aktuelle Neurologie (09). https://doi.org/10.1055/s-0028-1086672
Mit CareLit weiterarbeiten